about
Resistance to multiple novel antifolates is mediated via defective drug transport resulting from clustered mutations in the reduced folate carrier gene in human leukaemia cell linesStructure and function of ABCG2-rich extracellular vesicles mediating multidrug resistanceThe obligatory intestinal folate transporter PCFT (SLC46A1) is regulated by nuclear respiratory factor 1.Heterogeneous nuclear ribonucleoprotein H1/H2-dependent unsplicing of thymidine phosphorylase results in anticancer drug resistanceThe reduced folate carrier (RFC) is cytotoxic to cells under conditions of severe folate deprivation. RFC as a double edged sword in folate homeostasisHeterodimerization, altered subcellular localization, and function of multiple zinc transporters in viable cells using bimolecular fluorescence complementationThe role of multidrug resistance efflux transporters in antifolate resistance and folate homeostasis.Molecular Basis of Transient Neonatal Zinc Deficiency: NOVEL ZnT2 MUTATIONS DISRUPTING ZINC BINDING AND PERMEATION.The folate receptor as a rational therapeutic target for personalized cancer treatment.Reduced folate carrier gene silencing in multiple antifolate-resistant tumor cell lines is due to a simultaneous loss of function of multiple transcription factors but not promoter methylation.Alterations in the expression of transcription factors and the reduced folate carrier as a novel mechanism of antifolate resistance in human leukemia cells.Loss of folylpoly-gamma-glutamate synthetase activity is a dominant mechanism of resistance to polyglutamylation-dependent novel antifolates in multiple human leukemia sublines.Lysosomes as mediators of drug resistance in cancer.Folylpolyglutamate synthetase splicing alterations in acute lymphoblastic leukemia are provoked by methotrexate and other chemotherapeutics and mediate chemoresistance.Folylpoly-γ-glutamate synthetase: A key determinant of folate homeostasis and antifolate resistance in cancer.The role of the zinc transporter SLC30A2/ZnT2 in transient neonatal zinc deficiency.Riboflavin concentration within ABCG2-rich extracellular vesicles is a novel marker for multidrug resistance in malignant cells.PCFT/SLC46A1 promoter methylation and restoration of gene expression in human leukemia cells.C421 allele-specific ABCG2 gene amplification confers resistance to the antitumor triazoloacridone C-1305 in human lung cancer cells.Mutant Gly482 and Thr482 ABCG2 mediate high-level resistance to lipophilic antifolates.Probing ATP-dependent conformational changes in the multidrug resistance protein 1 (MRP1/ABCC1) in live tumor cells with a novel recombinant single-chain Fv antibody targeted to the extracellular N-terminus.Disruption of transport activity in a D93H mutant thiamine transporter 1, from a Rogers Syndrome family.Lysosomal accumulation of anticancer drugs triggers lysosomal exocytosis.Structural recognition of tubulysin B derivatives by multidrug resistance efflux transporters in human cancer cells.Severe hypoxia induces complete antifolate resistance in carcinoma cells due to cell cycle arrest.Multiple mechanisms of resistance to methotrexate and novel antifolates in human CCRF-CEM leukemia cells and their implications for folate homeostasis.Beta-casein nanovehicles for oral delivery of chemotherapeutic drugs.Hereditary folate malabsorption: a positively charged amino acid at position 113 of the proton-coupled folate transporter (PCFT/SLC46A1) is required for folic acid binding.Aberrant splicing of folylpolyglutamate synthetase as a novel mechanism of antifolate resistance in leukemia.Novel extracellular vesicles mediate an ABCG2-dependent anticancer drug sequestration and resistance.Computer modelling of antifolate inhibition of folate metabolism using hybrid functional petri nets.LysoTracker and MitoTracker Red are transport substrates of P-glycoprotein: implications for anticancer drug design evading multidrug resistance.Role of proton-coupled folate transporter in pemetrexed resistance of mesothelioma: clinical evidence and new pharmacological tools.Cancer cell-selective, clathrin-mediated endocytosis of aptamer decorated nanoparticles.Potentiation of anticancer-drug cytotoxicity by multidrug-resistance chemosensitizers involves alterations in membrane fluidity leading to increased membrane permeability.The JmjN domain as a dimerization interface and a targeted inhibitor of KDM4 demethylase activity.β-Casein micelles for oral delivery of SN-38 and elacridar to overcome BCRP-mediated multidrug resistance in gastric cancerDemonstrating aspects of multiscale modeling by studying the permeation pathway of the human ZnT2 zinc transporterLysosomotropic drugs activate TFEB via lysosomal membrane fluidization and consequent inhibition of mTORC1 activitySurmounting Cytarabine-resistance in acute myeloblastic leukemia cells and specimens with a synergistic combination of hydroxyurea and azidothymidine
P50
Q24534739-CC18A5D9-B7EC-4265-9D82-7DC3877766B9Q27437985-3B4725BE-EDC1-4FDA-AEE2-11474BAC9529Q34132226-9F3C1293-7D1E-48C8-8775-F6255CF75181Q34536974-6D3BF042-B37C-41D9-A6C4-B39709B579DBQ34656357-0FC95AF4-1763-40F7-98EF-D5DE7026A04CQ35580837-353545B9-2BAA-477F-A0C1-8203CFCD04FAQ36648346-2DFB2481-3B82-4AF4-A61A-3AC572C9AC50Q37034380-B754D46B-928A-42E2-9875-6251F824CBDDQ38280014-CC89F1F4-6BF4-4814-B2A7-220C144CEDF6Q38349388-D69343FC-1D1A-4BF8-BFB7-DFBA44AF5BCBQ38358891-962D8A05-EA32-44FC-BD71-D0E458D8FA8BQ38359462-8C0B40A7-221B-40F8-8996-0275392C671EQ38718017-A8331FAD-1FF3-4068-8F33-9FDF38518193Q38821227-AF225488-44A3-446A-9A4E-3B293DE63BA9Q38952756-FFFB01E8-D42F-4D9D-B07E-F8FC224F5A68Q39406979-4ABA2183-4ED1-4723-8B8F-175686977124Q39896425-997613C7-8A11-416D-8734-4AB8BC9B079BQ39935745-993815BB-1211-47E0-9725-306F71F74E09Q40137056-2FCCCEC9-D404-4818-B84F-41387F9AFF76Q40292892-1979224E-FCBF-4604-9D2D-A4949A1DBEA8Q40433413-340F739F-434C-4DE0-A3C2-609D4352C366Q40616120-C3B58EC2-6C43-4F92-A5B9-42F395CE2148Q41233173-DA9339EE-1D24-418E-A32F-2B6E53AE0BE4Q41472858-28CFED5F-E29F-4A37-B05D-17BE5B391E03Q42003221-FB1D522C-9972-4962-8B4B-7915C3C5D302Q43883948-C0CA4526-BFC9-4D93-82AA-650B8927ACBCQ45926005-4A251E1D-7A10-4B66-916B-9E2D4004233BQ45976367-9FC180B6-490D-4F37-A740-DA7A393EB49CQ46170702-000A9125-3792-46B6-872E-ACE0277E2A58Q46831039-18CF61AB-4368-4B04-81AF-B07D7986F521Q46849545-B57D1D3A-4CFE-4AFF-966A-6AF8275AAF76Q47707597-E04BFBFB-8C0E-4E00-A08C-4E07A5386C3CQ47747410-54FA9C7F-C9B6-404F-B8D8-9BA94DD14C30Q53681649-DA9055F9-D323-422E-80A3-6B536721DC5DQ54177634-1B0DB234-C52F-4E1E-B18C-2DF61E640030Q55317864-D6A77E87-3047-43FE-B334-75A1F1F38D56Q58118236-D612DF8A-2153-4F03-9311-2F361C807995Q58617892-8067EAE0-2648-4117-970F-62598F2E6107Q60044948-668ECB6B-2C38-4CF6-9AC9-123A18EDC7BEQ64052506-75DC9E00-9A40-42A4-B926-AC1FB5B63A7D
P50
description
hulumtues
@sq
onderzoeker
@nl
researcher
@en
հետազոտող
@hy
name
Yehuda G Assaraf
@ast
Yehuda G Assaraf
@en
Yehuda G Assaraf
@es
Yehuda G Assaraf
@nl
Yehuda G Assaraf
@sl
type
label
Yehuda G Assaraf
@ast
Yehuda G Assaraf
@en
Yehuda G Assaraf
@es
Yehuda G Assaraf
@nl
Yehuda G Assaraf
@sl
prefLabel
Yehuda G Assaraf
@ast
Yehuda G Assaraf
@en
Yehuda G Assaraf
@es
Yehuda G Assaraf
@nl
Yehuda G Assaraf
@sl
P106
P21
P31
P496
0000-0001-6692-8221
P569
2000-01-01T00:00:00Z